A phase II trial to evaluate the efficacy and safety of CTP-354 in patients with spasticity associated with multiple sclerosis

Trial Profile

A phase II trial to evaluate the efficacy and safety of CTP-354 in patients with spasticity associated with multiple sclerosis

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs CTP 354 (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2014 This trial is expected to be initiated by the end of 2014, according to a Concert Pharmaceuticals media release.
    • 06 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top